Related Experiment Videos
Cell death/proliferation roles for nc886, a non-coding RNA, in the protein kinase R pathway in cholangiocarcinoma
1Department of Biochemistry and Molecular Biology, The University of Texas Medical Branch, Galveston, TX 77555-1072, USA.
Abstract:
We have recently identified nc886 (pre-miR-886 or vtRNA2-1) as a novel type of non-coding RNA that inhibits activation of protein kinase R (PKR). PKR's pro-apoptotic role through eukaryotic initiation factor 2 α (eIF2α) phosphorylation is well established in the host defense against viral infection. Paradoxically, some cancer patients have elevated PKR activity; however, its cause and consequence are not understood. Initially, we evaluated the expression of nc886, PKR and eIF2α in non-malignant cholangiocyte and cholangiocarcinoma (CCA) cells. nc886 is repressed in CCA cells and this repression is the cause of PKR's activation therein. nc886 alone is necessary and sufficient for suppression of PKR via direct physical interaction. Consistently, artificial suppression of nc886 in cholangiocyte cells activates the canonical PKR/eIF2α cell death pathway, suggesting a potential significance of the nc886 suppression and the consequent PKR activation in eliminating pre-malignant cells during tumorigenesis. In comparison, active PKR in CCA cells does not induce phospho-eIF2α nor apoptosis, but promotes the pro-survival nuclear factor-κB pathway. Thus, PKR has a dual life or death role during tumorigenesis. Similarly to the CCA cell lines, nc886 tends to be decreased but PKR tends to be activated in our clinical samples from CCA patients. Collectively from our data, we propose a tumor surveillance model for nc886's role in the PKR pathway during tumorigenesis.
Insights
A novel non-coding RNA, nc886, inhibits protein kinase R (PKR) activation. nc886 repression in cancer activates PKR, influencing cell survival or death pathways during tumorigenesis.
Area of Science:
- Molecular Biology
- Cancer Research
- RNA Biology
Background:
- Protein kinase R (PKR) plays a role in host defense via apoptosis.
- The function of elevated PKR activity in cancer is unclear.
- nc886 is a newly identified non-coding RNA regulating PKR.
Purpose of the Study:
- To investigate the role of nc886 in regulating PKR during cholangiocarcinoma (CCA) development.
- To elucidate the dual role of PKR in tumorigenesis.
- To propose a tumor surveillance model involving nc886 and PKR.
Main Methods:
- Expression analysis of nc886, PKR, and eIF2α in non-malignant and CCA cells.
- Assessing nc886's ability to suppress PKR through direct interaction.
- Evaluating the impact of nc886 suppression on cell death pathways.
- Analyzing clinical samples from CCA patients.
Main Results:
- nc886 is repressed in CCA cells, leading to PKR activation.
- nc886 directly interacts with and suppresses PKR.
- Suppression of nc886 in normal cells activates the pro-apoptotic PKR/eIF2α pathway.
- In CCA cells, active PKR promotes the pro-survival NF-κB pathway, not apoptosis.
- Reduced nc886 and activated PKR are observed in clinical CCA samples.
Conclusions:
- nc886 acts as a tumor suppressor by inhibiting PKR.
- PKR exhibits a dual role in tumorigenesis, promoting cell death in early stages and survival in later stages.
- A model of nc886-mediated tumor surveillance through the PKR pathway is proposed.
Related Concept Videos
The Intrinsic Apoptotic Pathway
Abnormal Proliferation
The Extrinsic Apoptotic Pathway
Negative Regulator Molecules
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...